Literature DB >> 18319339

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.

Daniel E Speiser1, Petra Baumgaertner, Verena Voelter, Estelle Devevre, Catherine Barbey, Nathalie Rufer, Pedro Romero.   

Abstract

Human cancer vaccines are often prepared with altered "analog" or "heteroclitic" antigens that have been optimized for HLA class I binding, resulting in enhanced immunogenicity. Here, we take advantage of CpG oligodeoxynucleotides as powerful vaccine adjuvants and demonstrate the induction of high T cell frequencies in melanoma patients, despite the use of natural (unmodified) tumor antigenic peptide. Compared with vaccination with analog peptide, natural peptide induced T cell frequencies that were approximately twofold lower. However, T cells showed superior tumor reactivity because of (i) increased functional avidity for natural antigen and (ii) enhancement of T cell activation and effector function. Thus, novel vaccine formulations comprising potent immune stimulators may allow to circumvent the need for modified antigens and can induce highly functional T cells with precise antigen specificity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319339      PMCID: PMC2268830          DOI: 10.1073/pnas.0800080105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Tumour immunology.

Authors:  Thierry Boon; Benoit Van den Eynde
Journal:  Curr Opin Immunol       Date:  2003-04       Impact factor: 7.486

2.  Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells.

Authors:  Timothy N J Bullock; David W Mullins; Victor H Engelhard
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

3.  A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.

Authors:  Vinod Pullarkat; Peter P Lee; Ronaldo Scotland; Valerie Rubio; Susan Groshen; Conway Gee; Roy Lau; Jolie Snively; Shirley Sian; Susan L Woulfe; Richard A Wolfe; Jeffrey S Weber
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

4.  Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

Authors:  J L Chen; P R Dunbar; U Gileadi; E Jäger; S Gnjatic; Y Nagata; E Stockert; D L Panicali; Y T Chen; A Knuth; L J Old; V Cerundolo
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

Authors:  Susanne G Schaed; Virginia M Klimek; Katherine S Panageas; Cristina M Musselli; Leah Butterworth; Wen-Jen Hwu; Philip O Livingston; Linda Williams; Jonathan J Lewis; Alan N Houghton; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

6.  Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.

Authors:  Danila Valmori; Valerie Dutoit; Valerie Schnuriger; Anne-Lise Quiquerez; Mikaël J Pittet; Philippe Guillaume; Verena Rubio-Godoy; Paul R Walker; Donata Rimoldi; Danielle Liénard; Jean-Charles Cerottini; Pedro Romero; Pierre-Yves Dietrich
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

7.  Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.

Authors:  Maha Ayyoub; Alfred Zippelius; Mikaël J Pittet; Donata Rimoldi; Danila Valmori; Jean-Charles Cerottini; Pedro Romero; Ferdy Lejeune; Danielle Liénard; Daniel E Speiser
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

8.  Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.

Authors:  John W Smith; Edwin B Walker; Bernard A Fox; Daniel Haley; Ketura P Wisner; Teri Doran; Brenda Fisher; Lisa Justice; William Wood; John Vetto; Holden Maecker; Annemiek Dols; Sybren Meijer; Hong-Ming Hu; Pedro Romero; W Gregory Alvord; Walter J Urba
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response.

Authors:  Martin Prlic; Gabriela Hernandez-Hoyos; Michael J Bevan
Journal:  J Exp Med       Date:  2006-08-14       Impact factor: 14.307

10.  Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.

Authors:  Valérie Dutoit; Verena Rubio-Godoy; Mikäel J Pittet; Alfred Zippelius; Pierre-Yves Dietrich; Frédérique Anne Legal; Philippe Guillaume; Pedro Romero; Jean-Charles Cerottini; Richard A Houghten; Clemencia Pinilla; Danila Valmori
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

View more
  67 in total

Review 1.  New approaches to design HIV-1 T-cell vaccines.

Authors:  Hélène Perrin; Glenda Canderan; Rafick-Pierre Sékaly; Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.

Authors:  Matthias Wölfl; Katharina Merker; Henner Morbach; Stefaan W Van Gool; Matthias Eyrich; Philip D Greenberg; Paul G Schlegel
Journal:  Cancer Immunol Immunother       Date:  2010-10-24       Impact factor: 6.968

3.  Cancer Vaccines 2007. Cancer and HIV Vaccines: Shared Lessons. October 4-6, 2007, New York, USA. Abstracts.

Authors: 
Journal:  Cancer Immun       Date:  2008

4.  Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35.

Authors:  Marion Tarbe; John J Miles; Emily S J Edwards; Kim M Miles; Andrew K Sewell; Brian M Baker; Stéphane Quideau
Journal:  ChemMedChem       Date:  2020-04-06       Impact factor: 3.466

5.  Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.

Authors:  Yuan Hong; Yibing Peng; Z Sheng Guo; Jose Guevara-Patino; Junfeng Pang; Lisa H Butterfield; Nahid F Mivechi; David H Munn; David L Bartlett; Yukai He
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

6.  TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.

Authors:  Mathilde Allard; Barbara Couturaud; Laura Carretero-Iglesia; Minh Ngoc Duong; Julien Schmidt; Gwennaëlle C Monnot; Pedro Romero; Daniel E Speiser; Michael Hebeisen; Nathalie Rufer
Journal:  JCI Insight       Date:  2017-07-20

7.  Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes.

Authors:  Amalie Kai Bentzen; Andrea Marion Marquard; Rikke Lyngaa; Sunil Kumar Saini; Sofie Ramskov; Marco Donia; Lina Such; Andrew J S Furness; Nicholas McGranahan; Rachel Rosenthal; Per Thor Straten; Zoltan Szallasi; Inge Marie Svane; Charles Swanton; Sergio A Quezada; Søren Nyboe Jakobsen; Aron Charles Eklund; Sine Reker Hadrup
Journal:  Nat Biotechnol       Date:  2016-08-29       Impact factor: 54.908

8.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Authors:  Steffen Walter; Toni Weinschenk; Arnulf Stenzl; Romuald Zdrojowy; Anna Pluzanska; Cezary Szczylik; Michael Staehler; Wolfram Brugger; Pierre-Yves Dietrich; Regina Mendrzyk; Norbert Hilf; Oliver Schoor; Jens Fritsche; Andrea Mahr; Dominik Maurer; Verona Vass; Claudia Trautwein; Peter Lewandrowski; Christian Flohr; Heike Pohla; Janusz J Stanczak; Vincenzo Bronte; Susanna Mandruzzato; Tilo Biedermann; Graham Pawelec; Evelyna Derhovanessian; Hisakazu Yamagishi; Tsuneharu Miki; Fumiya Hongo; Natsuki Takaha; Kosei Hirakawa; Hiroaki Tanaka; Stefan Stevanovic; Jürgen Frisch; Andrea Mayer-Mokler; Alexandra Kirner; Hans-Georg Rammensee; Carsten Reinhardt; Harpreet Singh-Jasuja
Journal:  Nat Med       Date:  2012-07-29       Impact factor: 53.440

Review 9.  Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.

Authors:  Jeanne Menez-Jamet; Catherine Gallou; Aude Rougeot; Kostas Kosmatopoulos
Journal:  Ann Transl Med       Date:  2016-07

10.  Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Authors:  Cedrik Michael Britten; Sylvia Janetzki; Leah Ben-Porat; Timothy M Clay; Michael Kalos; Holden Maecker; Kunle Odunsi; Michael Pride; Lloyd Old; Axel Hoos; Pedro Romero
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.